Immune system ‘overdrive’ in pregnant women puts male child at risk for brain disorders
Johns Hopkins researchers report that fetal mice - especially males - show signs of brain damage that lasts into their adulthood when they are exposed in the womb to a maternal immune system kicked into high gear by a serious infection or other malady. The findings suggest that some neurologic diseases in humans could be similarly rooted in prenatal exposure to inflammatory immune responses.
In a report on the research published online last week in the journal Brain, Behavior and Immunity, the investigators say that the part of the brain responsible for memory and spatial navigation (the hippocampus) was smaller over the long term in the male offspring exposed to the overactive immune system in the womb. The males also had fewer nerve cells in their brains and their brains contained a type of immune cell that shouldn’t be present there.
“Our research suggests that in mice, males may be more vulnerable to the effects of maternal inflammation than females, and the impact may be life long,” says study leader Irina Burd, M.D., Ph.D., an assistant professor of gynecology/obstetrics and neurology at the Johns Hopkins University School of Medicine and director of the Integrated Research Center for Fetal Medicine. “Now we wonder if this could explain why more males have diseases such as autism and schizophrenia, which appear to have neurobiological causes.”
For the study, researchers sought to mimic the effects of a maternal infection or other condition that causes inflammation in a pregnant mother. This type of inflammation between 18 and 32 weeks of gestation in humans has been linked to preterm birth as well as an imbalance of immune cells in the brain of the offspring and even death of nerve cells in the brains of those children. Burd and her colleagues used a mouse model to study what happens to the brains of those offspring as they age into adulthood to see if the effects persisted.
One group of pregnant mice got saline injections into the womb, while another group got injections of lipopolysaccharide (LPS), a toxin meant to generate the kind of inflammatory effects of E. coli bacteria without the presence of the germ itself.
Soon after birth, the LPS group showed poor motor skills and behavioral issues such as hyperactivity. At 60 days post-weaning - the equivalent of mouse adulthood - the LPS mice could walk well, but were still hyperactive, suggesting the motor problems had resolved, possibly through some type of rewiring of the brain, but the behavioral problems had not.
“All this time later, something was still going on in their brains,” Burd says.
The sex-specific differences - the smaller hippocampus, the presence of fewer nerve cells, the existence of immune system macrophages in places they shouldn’t be - were also found in adulthood.
Chronic inflammation, Burd says, may play a role in keeping the hippocampus small, potentially because it inhibits proper brain development. But why males and females respond differently to the same insult in utero remains a question.
Unraveling the sex-based mechanisms underlying the response to maternal inflammation could provide critical knowledge necessary to develop interventions and potentially new drug therapies, she says.
Other Johns Hopkins researchers involved in the study include Tahani Dada, M.D.; Jason M. Rosenzweig, Ph.D.; Mofeedah Al Shammary, M.D.; Wance Firdaus, Ph.D.; Shorouq Al Rebh, M.D.; Talaibek Borbiev, Ph.D.; Aylin Tekes, M.D.; Jiangyang Zhang, Ph.D.; Eman Alqahtani, M.D.; Susumu Mori, Ph.D.; Mikhail V. Pletnikov, M.D., Ph.D.; and Michael V. Johnston, M.D.
The research was supported by the Aramco Services Company Fellowship Fund, the National Institutes of Health’s National Institute of Child Health and Human Development (K08HD073315), National Institute of Neurological Disorders and Stroke (NS28208), National Institute of Biomedical Imaging and Bioengineering (R01 EB003543) and the Johns Hopkins Brain Science Institute.
For more information:
Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $6.7 billion integrated global health enterprise and one of the leading health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM’s vision, “Together, we will deliver the promise of medicine,” is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, and more than 30 primary health care outpatient sites. The Johns Hopkins Hospital, opened in 1889, was ranked number one in the nation for 21 years in a row by U.S. News & World Report.
Johns Hopkins Medicine
Tell-a-Friend comments powered by Disqus